TNFRSF17 and plasma cell myeloma: Anti-BCMA therapies currently being evaluated in clinical trials in patients with multiple myeloma include bispecific Ab constructs, which facilitate cell-to-cell interactions between malignant plasma cells and cytotoxic T cells.